Pharmacological agents, including vitamin E, SGLT-2 inhibitors, and PPAR agonists, have shown potential in addressing specific aspects of NASH but fail to comprehensively resolve inflammation and fibrosis. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.